Literature DB >> 15009083

Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia.

G Bartsch1, J M Fitzpatrick, J A Schalken, J Isaacs, J Nordling, C G Roehrborn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15009083     DOI： 10.1111/j.1464-410x.2004.04646.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  12 in total

1.  Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia.

Authors:  Kyoung Pyo Hong; Young Joon Byun; Hana Yoon; Young Yo Park; Woo Sik Chung
Journal:  Korean J Urol       Date:  2010-07-20

Review 2.  How should prostate specific antigen be interpreted?

Authors:  Ali Atan; Özer Güzel
Journal:  Turk J Urol       Date:  2013-09

Review 3.  Biomarkers for benign prostatic hyperplasia progression.

Authors:  Grant W Cannon; Robert H Getzenberg
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 4.  Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction.

Authors:  Serap Gur; Philip J Kadowitz; Wayne J G Hellstrom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Dutasteride: a review of its use in the management of prostate disorders.

Authors:  Susan J Keam; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  α-blocker monotherapy and α-blocker plus 5-alpha-reductase inhibitor combination treatment in benign prostatic hyperplasia; 10 years' long-term results.

Authors:  Teak Jun Shin; Chun Il Kim; Choal Hee Park; Byung Hoon Kim; Young Kee Kwon
Journal:  Korean J Urol       Date:  2012-04-18

7.  Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.

Authors:  Paul Toren; David Margel; Girish Kulkarni; Antonio Finelli; Alexandre Zlotta; Neil Fleshner
Journal:  BMJ       Date:  2013-04-15

Review 8.  Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.

Authors:  M Emberton; E B Cornel; P F Bassi; R O Fourcade; J M F Gómez; R Castro
Journal:  Int J Clin Pract       Date:  2008-05-08       Impact factor: 2.503

9.  Clinical effects of discontinuing 5-alpha reductase inhibitor in patients with benign prostatic hyperplasia.

Authors:  Won Kim; Jae Hung Jung; Tae Wook Kang; Jae Mann Song; Hyun Chul Chung
Journal:  Korean J Urol       Date:  2014-01-15

10.  Assessment of BPH/BOO.

Authors:  Altaf Mangera; Nadir I Osman; Christopher R Chapple
Journal:  Indian J Urol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.